[ U.S. CDMRP - Breast Cancer Era of Hope Scholar Award | Research Funding ]
Event details
| Date | 12.03.2020 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Breast Cancer Era of Hope Scholar Awards. These Awards will support individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity.
Experience in breast cancer research is not required; however, the application must focus on breast cancer. Individuals from other disciplines who will apply novel concepts to breast cancer are also encouraged to submit.
Considering the current breast cancer landscape and the BCRP’s mission, all FY20 BCRP Era of Hope Scholar Award applications must address at least one of the overarching challenges for FY20, which are listed at the end of this announcement.
Funding: max. $3’000’000
Duration: 4 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Applicants must be independent investigators no more than 6 years past their last training position.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, collaborators and key personnel, and a list of potential references as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 12-Mar-2020, 5:00 p.m. EST
Full Application Deadline: 26-Mar-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number:
W81XWH-20-BCRP-EOHS
Further information
FY20 Overarching Challenges
Experience in breast cancer research is not required; however, the application must focus on breast cancer. Individuals from other disciplines who will apply novel concepts to breast cancer are also encouraged to submit.
Considering the current breast cancer landscape and the BCRP’s mission, all FY20 BCRP Era of Hope Scholar Award applications must address at least one of the overarching challenges for FY20, which are listed at the end of this announcement.
Funding: max. $3’000’000
Duration: 4 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Applicants must be independent investigators no more than 6 years past their last training position.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, collaborators and key personnel, and a list of potential references as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 12-Mar-2020, 5:00 p.m. EST
Full Application Deadline: 26-Mar-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number:
W81XWH-20-BCRP-EOHS
Further information
- To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-20-BCRP-EOHS
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
FY20 Overarching Challenges
- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
- Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
- Eliminate the mortality associated with metastatic breast cancer
Practical information
- General public
- Free